Replies to post #368478 on Innovation Pharmaceuticals Inc (IPIX)

[ROMAD Diver]

Not in the top line data…this will be a brief telling of how we met the primary and maybe secondary endpoints. I expect that type of fidelity in the bottom line data.

[Blue Fin]

This kind of covers the varient field and everyone who has been on the sideline should read what it says, doesn't appear there are any varients as far as Brilacidin is concerned:

Brilacidin Human Coronavirus (H-CoV) Research: Scientists conducting laboratory testing of Brilacidin in endemic H-CoV strains (OC43, 229E, NL63) have informed the Company that they are reviewing potential venues to disseminate their findings, including conferences, via publication or through public release by the Company. These data show Brilacidin inhibits different H-CoV strains, supporting Brilacidin as a pan-coronavirus agent.

some May be wishing they had bought earlier.

[farrell90]

The protocol does not call for the testing of mutations/variants. The delta variant became the dominant variant during the trial so many patients probably had the delta variant.

https://www.nytimes.com/2021/06/18/world/europe/coronavirus-russia-delta-moscow.html.

GLTA Farrell